Photo credit: www.therobotreport.com
Wandercraft Launches Clinical Trial for Innovative Personal Exoskeleton
Wandercraft has initiated a clinical trial for its groundbreaking Personal Exoskeleton, a self-balancing device aimed at enhancing mobility for those with significant physical impairments. This cutting-edge technology is intended to empower individuals to stand, walk, bend, and reach, effectively restoring the experience of natural walking in daily life.
Clinical Trial Locations and Goals
The trial is currently taking place at the James J. Peters VA Medical Center in the Bronx, New York, with plans for another trial to commence soon at the Kessler Institute for Rehabilitation in West Orange, New Jersey. The purpose of this study is to evaluate both the safety and efficacy of the Personal Exoskeleton specifically for individuals facing spinal cord injuries (SCI).
Matthieu Masselin, CEO of Wandercraft, expressed enthusiasm regarding the significance of this trial, stating, “This launch marks a critical step in our mission to transform mobility technology. We have observed the incredible benefits our exoskeletons provide in rehabilitation settings, and we are eager to see how the Personal Exoskeleton could significantly enhance mobility and autonomy for those with severe walking challenges, starting with SCI patients, allowing them to navigate without aid from crutches or walkers.”
Features of the Personal Exoskeleton
The technology behind the Personal Exoskeleton is designed to respond to user movements in real-time, facilitating a seamless walking experience on various surfaces, including carpet, concrete, and tile. Wandercraft emphasizes that this device is not only about mobility but also about reclaiming everyday moments—be it walking down the aisle, engaging face-to-face with friends and family, or stepping into a new world of confidence.
Notable Public Demonstrations
During the 2024 Olympics, the Personal Exoskeleton played a noteworthy role in carrying the Olympic torch as part of the traditional relay. Kevin Piette, who typically relies on a wheelchair, made history as the first individual to utilize a self-balancing exoskeleton in this prestigious event.
Wandercraft’s Personal Exoskeleton. | Credit: Wandercraft
Eligibility and Volunteer Opportunities
The clinical trial welcomes adults aged 18 and over with either complete or incomplete motor SCI, specifically those with injuries at or above the T6 vertebra. Participants are required to have a physically capable companion who can assist during the sessions. In response to this need, Wandercraft is establishing a volunteer network to support trial participants. It is necessary for both patients and their companions to communicate effectively in English or with the aid of a translator.
For comprehensive details about the clinical trial, interested individuals can find more information here.
Those who fit the eligibility criteria or wish to volunteer as a companion are encouraged to reach out to: clinicaltrials@wandercraft.health. Further information can also be accessed at: https://clinicaltrials.gov/study/NCT06777576?term=wandercraft&rank=4.
Existing Products and Future Plans
Wandercraft is already known for its Atalante X exoskeleton, which has received clearance from the U.S. Food and Drug Administration for individuals with spinal cord injuries. This self-balancing robotic exoskeleton enables users with mobility limitations to stand and walk once more.
Additionally, Wandercraft has secured over €25 million (approximately $27 million) in funding from the European Investment Bank. This financial support is aimed at further developing the Personal Exoskeleton and enhancing patient access to the Atalante X device.
Source
www.therobotreport.com